Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ZYBT · Nasdaq · United States · Pharmaceutical Preparations
In shortZhengye Biotechnology Holding Ltd is loss-making, generates cash and holds more cash than debt, with revenue shrinking (−37.6% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -60.6% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -60.0% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -26.1% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -21.4% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.14× | 28/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.04× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -20.74× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.03 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 10.6% | 62/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 3 of 4 | 69/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 4 | 75/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 3 | 0/100 |
| Revenue growth volatility | 13.3% | 62/100 |
| Operating margin volatility | 40.1% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -23.5% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 4 fiscal years from the company's annual reports.
CNY millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 260 | 212 | 186 | 116 |
| Cost of revenue | 112 | 94 | 95 | 92 |
| Gross profit | 148 | 118 | 91 | 24 |
| Research & development | 13 | 12 | 13 | 18 |
| Operating income | 66 | 45 | 16 | (71) |
| Interest expense | 2.8 | 4.4 | 4 | 3.4 |
| Pre-tax income | 64 | 44 | 14 | (72) |
| Income tax | 8.2 | 6.3 | 0.9 | 11 |
| Net income | 47 | 31 | 11 | (70) |
| Diluted EPS | ¥1.02 | ¥0.69 | ¥0.25 | – |
| Diluted shares (millions) | 46 | 46 | 46 | 47 |
1.03 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
2/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 28, 2026